Deadline Alert: Insulet Corporation (PODD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay & Wolke LLP reminds investors of the upcoming August 31, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”).

On March 12, 2026, Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” On this news, Insulet’s stock price fell $16.23, or 6.9%, to close at $219.84 per share on March 13, 2026, thereby injuring investors.

Then, on May 26, 2026, Insulet announced the initiation of another “voluntary Medical Device Correction” for “specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.” On this news, Insulet’s stock price fell $7.79, or 5.1%, to close at $146.01 per share on May 27, 2026, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Insulet’s manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Insulet securities during the Class Period, you may move the Court no later than August 31, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.